Sökning: WFRF:(Westerberg Marcus) >
Survival Trend in I...
Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy
-
- Corsini, Christian (författare)
- Uppsala universitet,Institutionen för kirurgiska vetenskaper,Division of Experimental Oncology/Unit of Urology, URI Institution, IRCCS San Raffaele Hospital, Milan, Italy
-
- Garmo, Hans (författare)
- Uppsala universitet,Urologkirurgi
-
- Wilberg Orrason, Andri (författare)
- Uppsala universitet,Urologkirurgi
-
visa fler...
-
- Gedeborg, Rolf (författare)
- Uppsala universitet,Anestesiologi och intensivvård,Medical Products Agency, Stockholm, Sweden
-
- Stattin, Pär (författare)
- Uppsala universitet,Urologkirurgi
-
- Westerberg, Marcus, 1990- (författare)
- Uppsala universitet,Urologkirurgi
-
visa färre...
-
(creator_code:org_t)
- American Medical Association (AMA), 2023
- 2023
- Engelska.
-
Ingår i: JAMA Network Open. - : American Medical Association (AMA). - 2574-3805. ; 6:10
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- IMPORTANCE: Recently, life-prolonging treatments for patients with advanced prostate cancer have been introduced in clinical practice.OBJECTIVE: To investigate if the introduction of doublet therapy is associated with changes in survival on a population-basis.DESIGN, SETTING, AND PARTICIPANTS: This nationwide population-based cohort study used data from the Prostate Cancer data Base Sweden from 2008 to 2020. Men registered with de novo metastatic castration-sensitive prostate cancer (mCSPC) were included.EXPOSURE: The proportion of men with mCSPC who received doublet therapy, ie, androgen deprivation therapy plus androgen receptor pathway inhibitor drugs or chemotherapy was assessed.MAIN OUTCOMES AND MEASURES: Standardized overall survival, taking age, comorbidity, and cancer characteristics into consideration, was estimated by use of a parametric survival model.RESULTS: A total of 11 382 men were included in this study (median [IQR] age, 74.0 [68-81] years). There was a shift toward less advanced prostate cancer during the study period with a decrease in median (IQR) prostate-specific antigen at diagnosis in men with mCSPC from 145 (39-571) ng/mL to 107 (27-426) ng/mL. Upfront treatment with doublet therapy in these men simultaneously increased from 1% (7 of 991) in 2016 to 44% (402 of 922) in 2020. The adjusted 5-year overall survival increased from 26% (95% CI, 25%-28%) from 2008 to 2012 to 35% (95% CI, 31%-40%) from 2017 to 2020. During the first 5 years after diagnosis, there was an increase in mean survival of 6 months, from 2.7 (95% CI, 2.6-2.8) years from 2008 to 2012 to 3.2 (95% CI, 3.1-3.1) years from 2017 to 2020.CONCLUSIONS AND RELEVANCE: In parallel with improvements in treatment of advanced prostate cancer, a clinically meaningful increase in mean survival was observed in men with de novo mCSPC in Sweden between 2008 and 2020 in this study.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas